55559-75-6

Basic information

• Product Name: 1,3-Dioxolane-4-ethanol, 2,2-dimethyl-, 4-methylbenzenesulfonate
• Synonyms: 1,3-Dioxolane-4-ethanol,2,2-dimethyl-,4-methylbenzenesulfonate
• CAS NO: 55559-75-6
• Molecular Formula: C14H20O5S
• Molecular Weight: 300.376
• Mol File: 55559-75-6.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 1,3-Dioxolane-4-ethanol, 2,2-dimethyl-, 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dioxolane-4-ethanol, 2,2-dimethyl-, 4-methylbenzenesulfonate(55559-75-6)
• EPA Substance Registry System: 1,3-Dioxolane-4-ethanol, 2,2-dimethyl-, 4-methylbenzenesulfonate(55559-75-6)

Safety Data

• Hazardous Substances Data: 55559-75-6(Hazardous Substances Data)

Upstream product

• 5754-34-7 4-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxolane 
• 4124-41-8 p-toluenesulfonylanhydride 
• 167629-45-0 4-[2-(4-methoxy-benzyloxy)ethyl]-2,2-dimethyl-[1,3]dioxolane 
• 3068-00-6 D,L-1,2,4-butanetriol 
• 98-59-9 p-toluenesulfonyl chloride 
• 67-64-1 acetone 

Downstream Products

• 1192259-40-7 N,N-dibenzyl-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanamine 
• 953046-64-5 (+/-)-1,2-O-isopropylidene-4-O-(2-chloro-4-nitrophenyl)-1,2,4-butanetriol 
• 796853-59-3 (+/-)-1,2-O-isopropylydene-4-(4-nitrophenyloxy)-1,2-butanediol 
• 83968-02-9 2,2-dimethyl-4-vinyl-1,3-dioxolane 

Relevant articles and documents

Lipids, lipid compositions, and methods of using them

Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I). The invention also relates to compositions and uses for stealth lipids of formula (XI). Also provided are processes for making such compounds, compositions, and formulations, plus methods and uses of such compounds, compositions, and formulations to deliver biologically active agents to cells and/or tissues.

Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography

Increased activity of efflux transporters, e.g., P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), at the blood-brain barrier is a pathological hallmark of many neurological diseases, and the resulting multiple drug resistance represents a major clinical challenge. Noninvasive imaging of transporter activity can help to clarify the underlying mechanisms of drug resistance and facilitate diagnosis, patient stratification, and treatment monitoring. We have developed a metabolically activated radiotracer for functional imaging of P-gp/BCRP activity with positron emission tomography (PET). In preclinical studies, the tracer showed excellent initial brain uptake and clean conversion to the desired metabolite, although at a sluggish rate. Blocking with P-gp/BCRP modulators led to increased levels of brain radioactivity; however, dynamic PET did not show differential clearance rates between treatment and control groups. Our results provide proof-of-concept for development of prodrug tracers for imaging of P-gp/BCRP function in vivo but also highlight some challenges associated with this strategy.

CATIONIC LIPIDS AND USES THEREOF

Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.